|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||20.14 - 20.30|
|52 Week Range||18.93 - 31.29|
|PE Ratio (TTM)||17.86|
|Forward Dividend & Yield||0.80 (3.42%)|
|1y Target Est||N/A|
Full-year results from the UK retailer matched last month’s profit warning, with pre-tax profit dropping 23 per cent despite a 4 per cent improvement in sales as mobile phone margins collapsed. “Pleasingly, the UK performance was no worse than feared, but following the recent unscheduled trading update in May, there is little new news in today’s prelims and guidance for next year,” said Investec, which repeated its “hold” advice. “We await for further clarity on what the UK Mobile business will look like going forward, and whether it can be run profitably.
Christophe Weber, the first foreign-born chief executive officer of Japan’s Takeda Pharmaceutical Co., last month inked a $62 billion takeover of rare-disease drugmaker Shire Plc. The deal will reshape the 237-old, Osaka-based company into a global powerhouse. In a recent interview in Manhattan, the French-born CEO talked about exciting areas of research and the potential of China. It used to take years to get the Essential Drug List [a list of medicines covered by the national medical insurance] updated in China.
Christophe Weber says growth and innovation are the metrics to success in Takeda Pharmaceutical Co.’s $62 billion purchase of Shire Plc. The first order of business is bringing global shareholders around to Japan’s biggest-ever outbound takeover. The Takeda chief executive officer is facing a 21 percent drop in the stock price since the company disclosed its interest in March, while Shire is trading 9 pounds ($12) below the offer price of roughly 49 pounds a share. In an interview at Takeda’s new Tokyo headquarters, the French-born CEO discusses his push to sell the deal overseas -- and in Japan -- and plans to integrate the 237-year-old drugmaker with a London-listed company with mostly U.S.-based operations.
Takeda's stock fell 16 percent between its interest in Shire emerging and the agreement of terms in early May. It has since fallen another 5 percent, despite boss Christophe Weber having had the chance set out the full rationale. The cash-and-shares offer was worth about 49 pounds per Shire share based on Takeda's closing share price as the deal was inked on May 8. Shire itself is trading at about 40 pounds.
Founding families of established businesses have always played a unique role in Japan. Takeda Pharmaceutical’s planned £46bn acquisition of Ireland’s Shire. Takeda is not alone in facing such familial grievances.
A group of Takeda Pharmaceutical Co Ltd shareholders is trying to build support to block the $62 billion (46.4 billion pounds) acquisition of London-listed Shire Plc (SHP.L) at an extraordinary general meeting, a leading member of the group told Reuters on Monday. Takeda will hold the shareholder meeting later this year or early next year to approve an issue of new stock to help fund the Shire deal, making it a de facto vote on the deal itself. The 130 member group formed by ex-Takeda employees holds one percent of the drugmaker's shares, and needs to secure a third of shareholder votes.
A group of Takeda Pharmaceutical Co Ltd shareholders is trying to build support to block the $62 billion acquisition of London-listed Shire Plc (SHP.L) at an extraordinary general meeting, a leading member of the group told Reuters on Monday. Takeda will hold the shareholder meeting later this year or early next year to approve an issue of new stock to help fund the Shire deal, making it a de facto vote on the deal itself. The 130 member group formed by ex-Takeda employees holds one percent of the drugmaker's shares, and needs to secure a third of shareholder votes.
In November each year, the leaders of Japan’s oldest pharmaceutical companies have traditionally gathered in Osaka to pay their respects to the gods of medicine. Companies put aside their rivalries for a two-day religious festival at the tiny Sukunahikona Shinto shrine in Doshomachi, the historical centre of Japan’s pharmaceutical trade, which dates to the Edo period (1603—1867). Backed by tax breaks, Osaka and the Kansai region has been Japan’s traditional hub for pharmaceutical companies, universities and the latest research in biotechnology and stem cells.
Mr Hokugo, who delivered a similar talk to US investors last month, is in London to foment foreign pressure on Japanese companies to abandon their networks of cross-held shares and their “allegiant” shareholders — companies, banks and insurers they do business with, are linked to by history or have assembled precisely to protect management from any awkward minority shareholder resolutions.
Masakazu Takeda, PM of the Hennessy Japan Fund, is finding big returns in the land of the rising sun. Japan has endured a lost decade (or three), but Masakazu Takeda of the Hennessy Japan Fund ($440 million in assets), spots big opportunity. Japanese markets, which outperformed the United States last year, offer value to those prepared to hunt for undervalued companies.
Japanese drugmaker Takeda Pharmaceutical Co Ltd faces demands from disgruntled shareholders to put to a vote its $62-billion (46.8 billion pounds) acquisition of London-listed Shire (SHP.L) and do more to assuage concerns over the record-breaking deal. The deal "carries overly high risks to the company" given its size, 12 shareholders said in a proposal to be voted on at next month's annual shareholders' meeting, adding that new shares to be issued to fund the deal threaten "a danger of causing a great disadvantage to existing shareholders". The Shire deal and any future deals worth more than 1 trillion yen (£7 billion) should be put to a shareholder vote, says the proposal - which will need two thirds of votes at the meeting to pass, according to a Takeda spokesman.
Roche jumped early Monday on unsurprisingly strong data for its hemophilia treatment, Hemlibra — prodding shares of Shire to slip.
Exelixis (EXEL) is focused on the label expansion and life cycle management of the cabozantinib franchise in collaboration with Bristol-Myers Squibb (BMY) and Roche Holdings (RHHBY). The above diagram shows the rationale for studying cabozantinib in combination with immunotherapy in multiple cancer indications. Exelixis is currently evaluating the safety and preliminary activity, in terms of objective response rate and progression-free survival, of a combination of cabozantinib with nivolumab and a combination of cabozantinib with nivolumab and ipilimumab in advanced hepatocellular carcinoma (or HCC) indications in an ongoing Phase 2 trial.
For Christophe Weber, the boss of Japan's Takeda Pharmaceutical , securing a $62 billion (46 billion pound) deal last week to buy drugmaker Shire (SHP.L) at the fifth time of asking was the easy bit. At the same time he must win shareholders' support for the largest-ever overseas purchase by a Japanese company - something he told Reuters could be helped by bringing in one or more long-term, large strategic investor.
For Christophe Weber, the boss of Japan's Takeda Pharmaceutical , securing a $62 billion deal last week to buy drugmaker Shire (SHP.L) at the fifth time of asking was the easy bit. At the same time he must win shareholders' support for the largest-ever overseas purchase by a Japanese company - something he told Reuters could be helped by bringing in one or more long-term, large strategic investor.
This is pharma now, says Takeda Pharmaceutical Co. Chief Executive Officer Christophe Weber, and the outlook isn’t any better. Scale up, says the French executive who’s run Takeda since 2015 and is currently in London seeking investor support for its planned $62 billion takeover of Shire, whose gastroenterology, neuroscience and rare-disease businesses he says are critical to accelerating the company’s transformation. Just a week ago Takeda clinched a deal to take over Shire, a company that’s about 50 percent bigger than its Osaka-based buyer by market value.
After topping the $110 level in March 2018, shares of Nektar Therapeutics (NASDAQ:NKTR) are in a downtrend. It is worth noting that even though Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) and Endo International PLC (NASDAQ:ENDP) are starting to attract investors, NKTR stock is more attractive because of the drug’s inherent properties. Nektar collaborated with Bristol-Myers Squibb Company (NYSE:BMY) to develop NKTR-214 in clinical trials.
Japan's Takeda Pharmaceutical Co Ltd on Monday forecast a 17 percent drop in operating profit for the year through March 2019 as blood cancer drug Velcade looks set to face generic competition in the United States. The loss of Velcade's exclusivity will be partly offset by growing sales of bowel disease treatment Entyvio and heartburn and ulcer drug Takecab, but Takeda's lower overall profitability underscores the firm's need to bolster its drug pipeline. "It's always hard in a pharmaceutical company to synchronise your pipeline with your generic exposure," Takeda Chief Executive Christophe Weber said.
Takeda Pharmaceutical's £46bn (US$62bn) acquisition of London-listed rare-disease specialist Shire has prompted Japan’s top drugmaker to line up a US$30.85bn bridge loan, the largest raised in Asia to date. The jumbo financing is expected to provide opportunities for asset-hungry lenders, both domestic and international, to lend to Takeda either through syndication of the bridge or a refinancing planned within a year. JP Morgan is underwriting 50% of the financing, and MUFG and Sumitomo Mitsui Banking Corp are committing equally to the remainder.
Eli Lilly & Co. sees your $62 billion megadeal and raises you a … $1.6 billion purchase of a tiny cancer-drug developer. Two days after Takeda Pharmaceutical Co. Ltd. announced its seismic acquisition of Shire PLC, Lilly came along with a more modest, and arguably smarter, takeover of ARMO BioSciences Inc. It’s a contrast in M&A philosophies, and the market reaction so far has also been divergent: Lilly’s shares rose about 2 percent after the Thursday morning announcement, while Takeda’s have taken a beating since rumors of its Shire pursuit emerged.